http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2185176-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e1a15aaad844e8195d1bee2b83e483db http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bfdeb68a360fb8cf264f4cb4e4dc9c0 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-16 |
| filingDate | 2000-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2002-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5d4a1e19043e6a9160c91674a3a3246 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d14bc1d2e19eb19fdf151fd45542d6e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5c31d66aa7462bdf9b58368e0afa3a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_699725e35bd46ce60a1826bcf4c310dc |
| publicationDate | 2002-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2185176-C2 |
| titleOfInvention | Method for treating dystrophic corneal diseases and cornea transplantation diseases |
| abstract | FIELD: medicine. SUBSTANCE: method involves administering intramuscular injections of Dalargin preparation at a dose of 3 mg during 10 days in combination with intravenous administration of 10% Perfluoran emulsion. Premedication including 1.0 ml of Relanium and 65 mg of hydrocortisone is carried out 10-15 min before administering Perfluoran emulsion. Then wet oxygen is administered for breathing through mask in a flow of 6 l/min discharge rate. 10% Perfluoran emulsion is administered after testing allergic response at a rate of 40 drops per 1 min. No allergic response being observed, the rate is increased to 60 drops per 1 min. Oxygen supply is continued during the whole procedure of Perfluoran emulsion administration. 100 ml of Perfluoran emulsion is given during one session. Then Perfluoran emulsion administration is repeated 1-3 days later. EFFECT: stable clinical effectiveness. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021211006-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008091177-A1 |
| priorityDate | 2000-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.